ESPERION THERAPEUTICS INC (ESPR) Stock Income Statement
NASDAQ:ESPR - Nasdaq - US29664W1053 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 332.31M | 116.33M | 75.50M | 78.40M | 227.50M | |||
| Cost Of Goods | 68.60M | 43.27M | 27.00M | 14.20M | 2.40M | |||
| Gross Profit | 263.71M | 73.07M | 48.50M | 64.20M | 225.20M | |||
| Operating Expenses | 209.31M | 228.63M | 228.00M | 277.70M | 346.50M | |||
| Research and Development | 46.24M | 86.11M | 118.90M | 106.00M | 146.90M | |||
| Selling, General, and Administrative Expenses | 163.07M | 142.52M | 109.10M | 171.70M | 199.60M | |||
| Operating Income | 54.40M | -155.56M | -179.50M | -213.40M | -121.40M | |||
| Interest Income/Expense | -51.65M | -54.58M | -54.40M | -46.30M | -22.20M | |||
| Other Income/Expense | 422.00K | 891.00K | 300.00K | 3.90M | 0.00 | |||
| Non Recurring Items | -54.92M | N/A | N/A | -13.30M | N/A | |||
| Income Before Taxes | -51.74M | -209.25M | -233.70M | -269.10M | -143.60M | |||
| Net Income | -51.74M | -209.25M | -233.70M | -269.10M | -143.60M | |||
| EBITDA | 54.47M | -155.40M | -179.00M | -212.79M | -120.85M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.28 | -2.03 | -3.52 | -9.31 | -5.23 | |||
| Non GAAP EPS | -0.25 | -2.12 | -3.55 | -9.56 | -5.48 | |||
| Statistics | ||||||||
| Gross Profit Margin | 79.36% | 62.81% | 64.24% | 81.89% | 98.99% | |||
| Profit Margin | -15.57% | -179.87% | -309.54% | -343.24% | -63.12% | |||
| Operating Profit Margin | 16.37% | -133.72% | -237.75% | -272.19% | -53.36% | |||
All data in USD